| Code |
OSV00014W |
| ID Tag |
Rb470-150608-WS |
| Ordering info |
Order online using the shopping cart ("Add to Cooler"), by email to
sales@osenses.com
or fax to 61-8-827 0 8586 and pay via PayPal by
MasterCard or Visa. You can also provide us with your Purchase Order Number (PON) and pay by check or wire transfer. Alternatively contact our distributors.
This item is in our stock. The handling & shipping cost is $48 USD and the expected delivery time is within 5 business days worldwide.
 |
| Unit size |
100 µl |
| Immunogen |
A synthetic peptide from a cytoplasmic part of Vesicle-associated membrane protein-associated protein B (VAMP-B) conjugated to an immunogenic carrier protein was used as the immunogen. The peptide is homologous in many species including human, rat, mouse, zebra fish, bovine, xenopus and chicken. |
| Conjugate |
Unconjugated antibody |
| Accession |
VAMP-B_HUMAN
VAMP-B_RAT
VAMP-B_MOUSE |
| Also known as |
VAMP-associated protein B, VAMP-B, VAP-B, Vesicle-associated membrane protein-associated protein B/C, VAMP-associated protein B/C, VAMP-B/VAMP-C, VAP-B/VAP-C, VAPB |
| Background |
FUNCTION: May play a role in vesicle trafficking.
SUBUNIT: Homodimer, and heterodimer with VAPA. Interacts with VAMP1 and VAMP2.
SUBCELLULAR LOCATION: Cell membrane; Single-pass type IV membrane protein. Intracytoplasmic membrane; Single-pass type IV membrane protein. Note: Present in the plasma membrane and in intracellular vesicles.
TISSUE SPECIFICITY: Ubiquitous. Isoform 1 predominates.
DISEASE: Defects in VAPB are the cause of amyotrophic lateral sclerosis type 8 (ALS8). ALS8 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms.
DISEASE: Defects in VAPB are a cause of proximal adult autosomal dominant spinal muscular atrophy; also called late-onset spinal muscular atrophy Finkel type. Spinal muscular atrophies are neurodegenerative disorders characterized by degeneration of lower motor neurons, leading to progressive paralysis muscular atrophy. This form is a late- adult-onset form of the disease (after age 20 years). The patients show a benign course, most of them remaining ambulatory 10 to 40 years after clinical onset. |
| Host |
NZ white rabbit |
| Purity |
Whole serum |
| Clonality |
Polyclonal |
| Isotype |
Polyclonal, whole serum |
| Applications |
IHC, WB. A dilution of 1 : 300 to 1 : 4000 is recommended. The optimal dilution should be determined by the end user. |
| Specificity |
Appears to be specific for VAMP-B. |
| Spcs X-react. |
Human, rat, mouse. Other species not yet tested. |
| Format |
Lyophilised |
| Reconstitution |
Reconstitute in 100 µl of sterile water. Centrifuge to remove any insoluble material. |
| Storage |
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles. |
| Expiry Date |
12 months after reconstitution |
| Transportation |
This item will be shipped to you at ambient temperature in a lyophilised form. |
| References |
1. Nishimura Y, et al. Biochem. Biophys. Res. Commun. 254:21-26(1999).
2. Hu R.-M, et al. Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
3. Clark H.F, et al. Genome Res. 13:2265-2270(2003).
4. Deloukas P, et al. Nature 414:865-871(2001).
5. Gevaert K, et al. Nat. Biotechnol. 21:566-569(2003).
6. Olsen J.V, et al. Cell 127:635-648(2006).
7. Nousiainen M, et al. Proc. Natl. Acad. Sci. U.S.A. 103:5391-5396(2006). |
| Limitation |
For research use only |
Primary Antibodies
